The Effects of Yoga Practice on Exercise Capacity, Arterial Stiffness, Respiratory Function, Peripheral Muscle Strength, Posture and Quality of Life in Children With Cystic Fibrosis

November 5, 2026 updated by: Naciye Vardar-Yagli, Hacettepe University

The aim of this study is to investigate the effects of exercise training applied through telerehabilitation on exercise capacity, peripheral and respiratory muscle strength, arterial stiffness, posture and quality of life in children with cystic fibrosis.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The most common problems in patients with cystic fibrosis (CF) are increased bronchial secretions, reduced exercise tolerance and shortness of breath.

Exercise capacity is limited due to muscle dysfunction, inflammation and progressive respiratory disease. Cardiovascular complications are one of the long-term complications of CF. Increased arterial stiffness is an indicator of elevated cardiovascular risk. It has been shown that patients with CF have increased arterial stiffness compared to their healthy peers.

Exercise training has a positive effect on exercise capacity, respiratory function and quality of life in patients with CF. Studies have shown that exercise training applied using the telerehabilitation method increases exercise capacity and improves peripheral muscle function in patients with CF. Peripheral muscle function, functional capacity, arterial stiffness and posture have been assessed in patients with CF. Furthermore, studies have been performed on patients with CF involving exercise training via telerehabilitation.In addition, various studies have shown that yoga and aerobic exercise training have positive effects on arterial stiffness. Although there are only a few studies involving patients with CF who practise yoga, no study has been found that assesses the effects of yoga practise via telerehabilitation on exercise capacity, peripheral and respiratory muscle function, and arterial stiffness.The purpose of this study is to examine the effects of exercise training using telerehabilitation on exercise capacity, peripheral and respiratory muscle strength, arterial stiffness, posture and quality of life in children with CF.

Children were randomly assigned to three groups: The first group will receive online aerobic exercise training and yoga sessions. The second group will receive only aerobic exercise training.The third group will be informed about the importance of physical activity and will be given recommendations for physical activity. Participants' respiratory function, exercise capacity, arterial stiffness parameters, peripheral muscle function, posture and quality of life questionnaire will be evaluated initially and following an 8-week exercise programme.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

8 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 8-18 years with a diagnosis of cystic fibrosis (CF)
  • Access to online exercise training
  • Percent predicted of forced expiratory volume at one second (FEV1) > 40% in pulmonary function test

Exclusion Criteria:

  • Being diagnosed with acute pulmonary exacerbation at the time of study and /or within the last month.
  • Being physically or perceptually competent to exercise
  • Patients with allergic bronchopulmonary aspergillosis who were treated with systemic steroid therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Combined Group

aerobic exercise training and yoga sessions in patients with cystic fibrosis
Other: aerobic exercises + yoga

Patients will be performed online in groups of 3-4 participants supervised aerobic exercises and yoga sessions. Aerobic exercises will be applied for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when yoga sessions are not performed. The yoga sessions will consist of 30-40-minute sessions, with three sessions per week for eight weeks. The yoga sessions will consist of three core components - asana (postures), pranayama (breathing) and meditation (focus).
Experimental: aerobic group

only aerobic exercises in patients with cystic fibrosis
Other: aerobic exercises

Patients will be performed online in groups of 3-4 participants supervised only aerobic exercises Aerobic exercises will be applied for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week.
Experimental: control group

physical activity recommendations in patients with cystic fibrosis
Other: Physical activity recommendations

Patients will be informed of the benefits of physical activity and appropriate physical activity recommendations will be provided.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
six minute walk test
Time Frame: before the exercise training

the distance reached in the six-minute walk test
before the exercise training
six minute walk test
Time Frame: eigth week

the distance reached in the six-minute walk test
eigth week

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Arterial stiffness
Time Frame: before the exercise training

Arterial stiffness will be assessed non-invasively using the Mobil-O-GRAPH (I.E.M., Stolberg, Germany).
before the exercise training
Arterial stiffness
Time Frame: eight week

Arterial stiffness will be assessed non-invasively using the Mobil-O-GRAPH (I.E.M., Stolberg, Germany).
eight week
Respiratory muscle strength
Time Frame: before the exercise training

Respiratory muscle strength will be evaluated using mouth pressure device
before the exercise training
Respiratory muscle strength
Time Frame: eight week

Respiratory muscle strength will be evaluated using mouth pressure device
eight week
respiratory muscle endurance
Time Frame: before the exercise training

Respiratory muscle endurance will be assessed using constant load test
before the exercise training
respiratory muscle endurance
Time Frame: eight week

Respiratory muscle endurance will be assessed using constant load test
eight week
Pulmonary functions-FVC
Time Frame: before the exercise training

Forced vital capacity (FVC)
before the exercise training
Pulmonary functions-FVC
Time Frame: eight week

Forced vital capacity (FVC)
eight week
Pulmonary functions-FEV1
Time Frame: before the exercise training

Forced expiratory volume in the first second (FEV1)
before the exercise training
Pulmonary functions-FEV1
Time Frame: eigth week

Forced expiratory volume in the first second (FEV1)
eigth week
Pulmonary functions-FEV1/FVC
Time Frame: before the exercise training

FEV1/ FVC
before the exercise training
Pulmonary functions-FEV1/FVC
Time Frame: eight week

FEV1/ FVC
eight week
Pulmonary functions-FEF25-75
Time Frame: before the exercise training

Forced mid-expiratory flow (FEF25-75)
before the exercise training
Pulmonary functions-FEF25-75
Time Frame: eigth week

Forced mid-expiratory flow (FEF25-75)
eigth week
Peripheral muscle strength
Time Frame: before the exercise training

Peripheral muscle strength will be assessed using dynamometer
before the exercise training
Peripheral muscle strength
Time Frame: eigth week

Peripheral muscle strength will be assessed using dynamometer
eigth week
1 minute sit to stand test (STS) repetitions
Time Frame: before the exercise training

number of sit to stand for one minute is recorded
before the exercise training
1 minute sit to stand test (STS) repetitions
Time Frame: eight week

number of sit to stand for one minute is recorded
eight week
posture
Time Frame: before the exercise training

Posture will be assessed using Corbin Postural Assessment scale. Lateral and posterior views will be assessed (0 = absent,1 = mild, 2 = moderate, 3 = severe) and posture score will be determined as excellent(0-2), very good (3-4), good (5-7), fair (8-11)and poor (>12).
before the exercise training
posture
Time Frame: eigth week

Posture will be assessed using Corbin Postural Assessment scale. Lateral and posterior views will be assessed (0 = absent,1 = mild, 2 = moderate, 3 = severe) and posture score will be determined as excellent(0-2), very good (3-4), good (5-7), fair (8-11)and poor (>12).
eigth week
Quality of life assessment
Time Frame: before the exercise training

Quality of life will be assessed using the Cystic Fibrosis Questionnaire-Revised .The Cystic Fibrosis Questionnaire-Revised is a disease-specific health-related quality of life measure for children, adolescents with cystic fibrosis (CF). The questionnaire evaluate physical functioning, emotional functioning, social functioning, body image, eating disorders, treatment,respiratory symptoms and digestive symptoms. Score range is 0-100. Higher scores indicating higher health-related qualityof life.
before the exercise training
Quality of life assessment
Time Frame: eigth week

Quality of life will be assessed using the Cystic Fibrosis Questionnaire-Revised .The Cystic Fibrosis Questionnaire-Revised is a disease-specific health-related quality of life measure for children, adolescents with cystic fibrosis (CF). The questionnaire evaluate physical functioning, emotional functioning, social functioning, body image, eating disorders, treatment,respiratory symptoms and digestive symptoms. Score range is 0-100. Higher scores indicating higher health-related quality of life.
eigth week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hacettepe University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Naciye Vardar-Yagli, PhD, Hacettepe University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 10, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 5, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FTREK25/92

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings